Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

15.5K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
15.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DDX3X overexpression in mice can cause rapid tissue-specific toxicity and mortality.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Salt-Mediated Electro-Deformation of AAV Capsids Revealed by Nanopipette-Based Single-Particle Analysis.

Analytical chemistry·2026
Same author

FRRS1L gene replacement ameliorates disease phenotypes in the mouse model of developmental and epileptic encephalopathy 37.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

An AAV vector for glial cells.

Nature biotechnology·2026
Same author

Ring-Electrode AC Plasmonic Nanopore Sensing for DNA Load Characterization of Single Adeno-Associated Viruses.

Sensors (Basel, Switzerland)·2026
Same author

Enzymatic Synthesis of NAD<sup></sup>.

Current protocols·2026

Related Experiment Video

Updated: Nov 6, 2025

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome
11:15

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome

Published on: March 2, 2018

7.5K

Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice.

Sarah E Sinnett1,2, Emily Boyle1, Christopher Lyons1

  • 1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Brain : a Journal of Neurology
|May 5, 2021
PubMed
Summary

Gene therapy for Rett syndrome using miniMECP2 shows promise, but controlling gene expression is key. A novel regulatory element, miRARE, enhances safety without sacrificing efficacy in preclinical models.

Keywords:
AAVMECP2RettintrathecalmicroRNA

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.9K
Loss-of-Function Approach in the Embryonic Chick Retina by Using Tol2 Transposon-Mediated Transgenic Expression of Artificial microRNAs
06:58

Loss-of-Function Approach in the Embryonic Chick Retina by Using Tol2 Transposon-Mediated Transgenic Expression of Artificial microRNAs

Published on: May 18, 2022

1.2K

Related Experiment Videos

Last Updated: Nov 6, 2025

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome
11:15

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome

Published on: March 2, 2018

7.5K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.9K
Loss-of-Function Approach in the Embryonic Chick Retina by Using Tol2 Transposon-Mediated Transgenic Expression of Artificial microRNAs
06:58

Loss-of-Function Approach in the Embryonic Chick Retina by Using Tol2 Transposon-Mediated Transgenic Expression of Artificial microRNAs

Published on: May 18, 2022

1.2K

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Rett syndrome is an X-linked neurodevelopmental disorder.
  • MECP2 gene transfer shows therapeutic potential but faces challenges with overexpression toxicity.
  • Previous attempts using truncated MECP2 (miniMECP2) via AAV9 gene transfer demonstrated therapeutic effects but retained dose-dependent toxicity.

Purpose of the Study:

  • To develop a safer gene therapy for Rett syndrome by controlling miniMECP2 transgene overexpression.
  • To engineer a novel regulatory element that mitigates toxicity associated with MECP2 gene transfer.
  • To assess the efficacy and safety of a microRNA-responsive auto-regulatory element (miRARE) in a preclinical model.

Main Methods:

  • Development of a synthetic microRNA target panel (miRARE) integrated into the miniMECP2 gene expression cassette.
  • Utilizing a risk-driven viral genome design strategy involving high-throughput profiling and genome mining.
  • Evaluating the AAV9/miniMECP2-miRARE vector in adolescent Mecp2-/y knockout mice, assessing toxicity and therapeutic efficacy.

Main Results:

  • AAV9/miniMECP2 exhibited dose-dependent toxicity similar to previous vectors in adolescent mice.
  • Insertion of miRARE into the miniMECP2 cassette significantly improved the safety profile of gene transfer.
  • The miRARE element effectively controlled miniMECP2 overexpression without compromising therapeutic efficacy.
  • The regulatory system is self-contained, requiring no external drugs and not expressing exogenous miRNAs.

Conclusions:

  • The miRARE element represents a significant advancement in developing safer gene therapies for Rett syndrome by providing built-in control of transgene expression.
  • This auto-regulatory approach overcomes critical safety hurdles associated with MECP2 gene therapy.
  • The miRARE strategy holds potential for application in gene therapies targeting other dose-sensitive genes.